CRNX
Crinetics Pharmaceuticals, Inc.
NASDAQ · USHealthcareBiotechnology
$83.87+0.01%
Price as of Jul 20, 2026
CRNX financials
Crinetics Pharmaceuticals, Inc. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $7.7M | $1.0M | $4.0M | $4.7M |
| Cost of revenue | $1.1M | $0.00 | $0.00 | $0.00 |
| Gross profit | $6.6M | $1.0M | $4.0M | $4.7M |
| Operating expenses | $523.4M | $339.9M | $226.6M | $172.6M |
| Operating income | -$516.8M | -$338.9M | -$222.6M | -$167.9M |
| Net income | -$465.3M | -$298.4M | -$214.5M | -$163.9M |
| EBITDA | -$461.2M | -$295.6M | -$213.4M | -$162.9M |
| Basic EPS | $-4.95 | $-3.69 | $-3.69 | $-3.15 |
| Diluted EPS | $-4.95 | $-3.69 | $-3.69 | $-3.15 |
| Balance sheet | ||||
| Cash & equivalents | $101.5M | $264.5M | $54.9M | $32.7M |
| Total assets | $1.1B | $1.4B | $635.4M | $352.2M |
| Total liabilities | $143.4M | $109.8M | $96.2M | $35.8M |
| Stockholders’ equity | $992.1M | $1.3B | $539.1M | $316.3M |
| Total debt | $48.5M | $51.7M | $51.7M | $3.1M |
| Net debt | -$53.0M | -$212.8M | -$3.2M | -$29.6M |
| Cash flow | ||||
| Operating cash flow | -$377.9M | -$226.0M | -$166.3M | -$115.2M |
| Capital expenditure | -$5.8M | -$3.8M | -$4.7M | -$1.7M |
| Free cash flow | -$383.7M | -$229.8M | -$171.0M | -$116.9M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | $0.00 | $0.00 | $0.00 |